SC-AMSA, a wholly-owned subsidiary of Sumitomo Chemical, is a premier provider of high-purity, small-scale guide RNA (gRNA) solutions for the global biotechnology and pharmaceutical industries. Headquartered in Marlborough, Massachusetts—in the heart of the Greater Boston life sciences ecosystem—SC-AMSA specializes in the custom synthesis of gRNA at the 1 mg scale, delivering exceptional precision and consistency required for critical R&D and preclinical applications.

As a recognized leader in the gRNA landscape, SC-AMSA is distinguished by its advanced manufacturing capabilities and rigorous quality standards. We consistently achieve over 80% purity for sequences ranging from 100mer up to 140mer, enabling researchers to pursue complex gene-editing programs with confidence in targeting accuracy and experimental reproducibility. Our proximity to the Boston biotech hub allows us to work closely with customers as a local partner allowing us to offer in-person meetings on short notice and provide hands-on technical support.

The core advantage of SC-AMSA lies in its seamless scalability through the Sumitomo Chemical Group. To support an efficient transition from discovery to clinical development, we utilize the exact same synthetic and analytical methods as those used by Sumitomo Chemical. This alignment allows partners to move smoothly from initial milligram-scale samples at SC-AMSA to large-scale GMP manufacturing (exceeding 10 g) at Sumitomo Chemical’s world-class facilities. By maintaining methodological continuity, we help minimize technical hurdles and risks typically associated with tech transfer. This end-to-end support ensures quality and regulatory compliance across the entire drug development lifecycle.

SC-AMSA reflects Sumitomo Chemical ’s strong commitment to the gene-editing industry. By combining its specialized expertise with Sumitomo Chemical’s global manufacturing infrastructure, SC-AMSA provides the high-purity RNA foundation for the next generation of gene-editing therapies.